# Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma

> **NCT02495103** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 7 (actual)

## Conditions studied

- Renal Cell Carcinoma
- Hereditary Leiomyomatosis
- Renal Cell Cancer

## Interventions

- **DRUG:** Vandetanib
- **DRUG:** Metformin
- **DRUG:** Vandetanib/Metformin

## Key facts

- **NCT ID:** NCT02495103
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-08-26
- **Primary completion:** 2020-02-06
- **Final completion:** 2020-02-06
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Vandetanib is no longer available as Sanofi has decided not to provide additional drug. All subjects are off-study.
- **Last updated:** 2021-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02495103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02495103, "Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02495103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*